On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.

The stock continues to trade with elevated volatility following an explosive surge of over 100% on May 18, driven by accelerating commercialization of its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio previously announced a strategic partnership with Tenry Pharma granting exclusive commercialization rights for Paidakang in mainland China, with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million. Additionally, Tenry Pharma signed a cooperation agreement with Ark Health on May 12 for the online debut of the drug on its internet hospital platform.

PegBio is a biotechnology company focused on developing innovative therapies for chronic metabolic diseases. Its core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets type 2 diabetes and obesity markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)